What changed
Financials are thin here: the excerpt covers offering expenses, indemnification and exhibits, with no revenue or cash-flow figures disclosed. The real numbers live in the project disclosures, not this amendment.
Risks: pre-production developer with multi-year timelines to production, a selective mining IPO backdrop (Sinda opened ~10% below offer; CopperTech postponed), and one profile source describes GRML as also in cell and gene therapy — an inconsistency worth verifying.
Use of proceeds: not specified in this excerpt. Don't assume — wait for the full prospectus before modeling where the capital goes.
Bottom line: the Sarfartoq story is compelling — up to US$2.05B valuation, 118.6% pre-tax IRR — but this filing is administrative. Investors should demand project quality, execution capability and valuation discipline, not commodity narrative alone.
Why it matters
Financials are thin here: the excerpt covers offering expenses, indemnification and exhibits, with no revenue or cash-flow figures disclosed. The real numbers live in the project disclosures, not this